J and J Snack Foods Newswire

Comprehensive Real-Time News Feed for J and J Snack Foods.

Results 1 - 20 of 1,054 in J and J Snack Foods

  1. J&J Said to Weigh $250 Million Accord on More Hip LawsuitsRead the original story

    9 hrs ago | The Washington Post

    Johnson & Johnson may pay more than $250 million to resolve suits over its ASR hip implants that were excluded from a $2.5 billion settlement of similar claims last year over the device's failure, two people familiar with the accord said. J&J, the world's largest seller of health-care products, is weighing whether to settle more than 1,000 lawsuits over removals of the recalled hip implants that occurred after August 2013, said the people, who requested anonymity because they weren't authorized to speak publicly about the accord.

    Comment?

  2. J&J May Settle More Than 1,000 Additional Claims Over ImplantsRead the original story

    14 hrs ago | The Washington Post

    Johnson & Johnson may pay more than $250 million to resolve suits over its ASR hip implants that were excluded from a $2.5 billion settlement of similar claims last year over the device's failure, two people familiar with the accord said. J&J, the world's largest seller of health-care products, is weighing whether to settle more than 1,000 lawsuits over removals of recalled ASR hip implants that occurred after August 2013, said the people, who requested anonymity because they weren't authorized to speak publicly about the accord.

    Comment?

  3. J&J May Pay $250 Million to Settle 1,000 More Hip ClaimsRead the original story

    19 hrs ago | Bloomberg

    Michael Kelly, attorney for plaintiff Loren Kransky, holds up an ASR XL hip implant made by Johnson & Johnson during his opening statement to the jury at the trial of Kransky v. DePuy, at California Superior Court in Los Angeles on Jan. 25, 2013.

    Comment?

  4. Vaccine-makers and Ebola: Giving it a shotRead the original story w/Photo

    21 hrs ago | The Economist

    IN MAY 2013 GlaxoSmithKline , a British pharmaceuticals firm, bought a small Swiss vaccine-maker for $325m. It acquired Okairos because it had the technology to create vaccines that stimulate stronger than normal immune responses.

    Comment?

  5. Are You Nervous About a Market Crash? 3 Top Dividend Stocks for Steady IncomeRead the original story

    21 hrs ago | The Motley Fool

    Just because a stock has a high dividend doesn't mean the payout will stay that way if the market gets rough. Some companies are just better positioned than others to weather any economic storm.

    Comment?

  6. bioMeI rieux subsidiary receives approval for one-hour Ebola testRead the original story w/Photo

    Wednesday | Business Journal

    Production operators stand by tubes in a bioreactor as they prepare a cell culture for growing active Ebola vaccine substances in the laboratory of Bavarian Nordic A/S in Kvistgaard, Denmark. The vaccine, to combat the virus that has killed thousands in West Africa, combines a shot from Johnson & Johnson's Janssen unit in the Netherlands with one developed by Danish biotechnology company Bavarian Nordic, J&J said in a statement two days ago.

    Comment?

  7. Big Pharma seeks legal immunity for damages from experimental Ebola vaccinesRead the original story w/Photo

    Tuesday | NewsTarget.com

    The same drug manufacturers that stand to profit immensely from the sale of Ebola vaccines say they require full legal immunity from any potential lawsuits that might arise when people are harmed by various adverse effects from these "emergency" drugs. GlaxoSmithKline CEO Andrew Witty told World Health Organization Director-General Margaret Chan that his corporation, which is currently leading the way in producing Ebola vaccines, shouldn't have to shoulder any of the burden of responsibility for their safety.

    Comment?

  8. J&J Snack Foods Corp. Hits New 52-Week High at $100.50Read the original story

    Tuesday | AmericanBankingNews.com

    Shares of J&J Snack Foods Corp. hit a new 52-week high during trading on Tuesday , AmericanBankingNews.com reports. The company traded as high as $100.50 and last traded at $100.50, with a volume of 15,455 shares.

    Comment?

  9. Hurdles hinder race for an Ebola vaccineRead the original story

    Tuesday Oct 28 | Iol.co.za

    DRUGMAKERS sprinting to develop Ebola vaccines face a series of technical hurdles if they are to get millions of doses ready for use next year - assuming clinical trials are successful. The challenges include finding sufficient sterile capacity for filling and packaging finished vials, getting fast quality approvals from regulators, and building a supply chain in Africa for products that must be stored at minus 80oC.

    Comment?

  10. Pharma Biggies Vie for a Bigger Share of the Fast Growing Domestic...Read the original story

    Tuesday Oct 28 | PR.com

    Elder Pharma relaunches AMPM Mouthwash - also introduces a Specific Mouthwash for smokers/tobacco users. * Becomes 3rd major entity after J&J and Colgate in this field; targets 5% market share.

    Comment?

  11. More apartments going up to meet demandRead the original story w/Photo

    Monday Oct 27 | Greeley Tribune

    A multifamily complex nears completion in west Greeley. This complex is being constructed by J&J and Journey Homes.

    Comment?

  12. HurelA Corporation Completes Investment from Johnston Associates, Inc.Read the original story

    Sep 24, 2014 | B3C

    North Brunswick, NJ, USA, September 24, 2014 / B3C newswire / - Hurel Corporation , a world-leading provider of in vitro liver models and microfluidic assay platforms that improve the predictive reliability of pre-clinical drug development, today announced that Johnston Associates, Inc. of Princeton, New Jersey has become a participating investor in the Company's Series A-3 Preferred Stock financing. Hurel's lead private equity investor, Spring Mountain Capital, LP, of New York, led the A-3 round.

    Comment?

  13. J&J Speeds Ebola Vaccine Development and Expands ProductionRead the original story

    Friday Oct 24 | Biopharm

    Johnson & Johnson committed up to $200 million to accelerate and significantly expand the production of an Ebola vaccine program in development at its Janssen Pharmaceutical Companies. The company is closely collaborating with the World Health Organization , the National Institute of Allergy and Infectious Diseases , and other key stakeholders, governments, and public health authorities on the clinical testing, development, production, and distribution of the vaccine regimen.

    Comment?

  14. Ebola news roundup: NYC doc has it; can you get Ebola from a bowling...Read the original story w/Photo

    Friday Oct 24 | Business Journal

    New York City's first confirmed case of Ebola in a doctor who performed aid work in West Africa raises questions about his whereabouts in the 10 days since he returned to the United States. Bloomberg's Shelby Holliday reports on "Market Makers."

    Comment?

  15. Ebola and a post-9/11 research pushRead the original story w/Photo

    Thursday Oct 23 | Bloomberg

    Thomas Geisbert spent the '90s scraping together funds to work on an Ebola cure. Occasionally, he'd get enough to test a potential vaccine in primates, but the monkeys always died.

    Comment?

  16. J&J working on 2-shot Ebola vaccineRead the original story w/Photo

    Thursday Oct 23 | Journal Gazette

    NEW BRUNSWICK, N.J. Johnson & Johnson will begin safety testing in early January on a vaccine combination that could protect people from a strain of the deadly Ebola virus.

    Comment?

  17. J&J to spend up to $200M on Ebola vaccine programRead the original story

    Wednesday Oct 22 | Hawk Eye

    NEED EXTRA SPENDING MONEY? DELIVER THE HAWK EYE! For just a few houses in the morning you can earn extra income.

    Comment?

  18. Boston Scientific Completes Turnaround as Mahoney Pledges GrowthRead the original story

    Wednesday Oct 22 | The Washington Post

    Boston Scientific Corp., the second- biggest maker of heart-rhythm devices, is on pace to increase annual sales for the first time since 2009, marking the end of a downturn that saw net losses in seven of the past eight years. While the market for products such as defibrillators and drug-coated stents used to prop open clogged heart arteries are flat or shrinking, Boston Scientific's sales rose 5.5 percent and 9.1 percent, respectively, the company reported.

    Comment?

  19. Cheney in Post 9/11 Era May Be to Thank on Ebola VaccineRead the original story

    Wednesday Oct 22 | Bloomberg

    Thomas Geisbert spent the '90s scraping together funds to work on an Ebola cure. Occasionally, he'd get enough to test a potential vaccine in primates, but the monkeys always died.

    Comment?

  20. Boston Scientific Turnaround Complete, CEO Mahoney SaysRead the original story

    Wednesday Oct 22 | Bloomberg

    Boston Scientific Corp. , the second-biggest maker of heart-rhythm devices, is on pace to increase annual sales for the first time since 2009, marking the end of a downturn that saw net losses in seven of the past eight years. While the market for products such as defibrillators and drug-coated stents used to prop open clogged heart arteries are flat or shrinking, Boston Scientific's sales rose 5.5 percent and 9.1 percent, respectively, the company reported.

    Comment?